Extended Azithromycin for Premature Rupture of Membranes

This trial examines whether additional doses of azithromycin, an antibiotic, can improve outcomes for pregnant patients whose water breaks early between 22 and 28 weeks. Researchers aim to determine if extra doses enhance results compared to standard treatment alone. Participants will be divided into two groups: one receiving the standard treatment and the other receiving extra azithromycin doses. Ideal participants are those with a single pregnancy, whose water broke early, and who are hospitalized with the expectation of continuing their pregnancy. As a Phase 4 trial, this research focuses on understanding how an already FDA-approved and effective treatment can benefit more patients.

The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are on ongoing alternative antibiotic treatment or drugs that significantly prolong the QT interval.

Research has shown that azithromycin is generally safe for pregnant individuals with preterm premature rupture of membranes (PPROM). Studies indicate that both azithromycin and erythromycin are well-tolerated, with no major safety differences.

Extended use of azithromycin has been linked to a longer time before delivery without serious side effects, suggesting it might help extend pregnancy safely. Although some research suggests that a single dose does not improve outcomes compared to standard care, extended use remains safe.

Researchers are excited about the Extended Azithromycin Regimen for premature rupture of membranes because it adds a new twist to the standard antibiotic treatment. While the usual care involves a single dose of azithromycin alongside ampicillin and amoxicillin, this regimen extends azithromycin administration to seven additional doses every other day. This extended dosing could potentially offer enhanced protection against infection, providing better outcomes for mothers and babies. By prolonging azithromycin use, researchers hope to explore if this approach leads to more effective infection control in these critical cases.

This trial will compare two treatment regimens for managing preterm prelabor rupture of membranes (PPROM). The Standard Antibiotic Regimen includes a single dose of oral azithromycin 1 gram at the time of presentation, along with standard intravenous ampicillin and oral amoxicillin. The Extended Azithromycin Regimen adds azithromycin 500 mg every other day for 7 additional doses to the standard regimen. Studies have shown that azithromycin can help manage PPROM by lowering the risk of infections like chorioamnionitis and postpartum endometritis, which can occur after the membranes break. Some studies found that azithromycin works as well as erythromycin, another common antibiotic for this condition. Clinical practice guidelines recommend using azithromycin in these cases. Overall, adding azithromycin to the treatment plan is believed to improve outcomes by reducing the risk of infections.²³⁴⁵⁶